Results 31 to 40 of about 59,816 (256)

Amiodarone

Reactions Weekly, 2012
Hoofnagle JH.
europepmc   +2 more sources

Investigating the suitability of high content image analysis as a tool to assess the reversibility of foamy alveolar macrophage phenotypes in vitro. [PDF]

, 2020
Many potential inhaled medicines fail during development due to the induction of a highly vacuolated or “foamy” alveolar macrophage phenotype response in pre-clinical studies.
Hoffman, Ewelina, Hutter, Victoria, Murnane, Darragh   +2 more
core   +2 more sources

Amiodarone Use and All‐Cause Mortality in Patients With a Continuous‐Flow Left Ventricular Assist Device

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022
Background Atrial and ventricular arrhythmias are commonly encountered in patients with advanced heart failure, with amiodarone being the most commonly used antiarrhythmic drug in continuous‐flow left ventricular assist device (CF‐LVAD) recipients.
Rakesh Gopinathannair, Naga Venkata K. Pothineni, Jaimin R. Trivedi, Henri Roukoz, Jennifer Cowger, Mustafa M. Ahmed, Adarsh Bhan, Ashwin K. Ravichandran, Geetha Bhat, Amin Al Ahmad, Andrea Natale, Luigi Di Biase, Mark S. Slaughter, Dhanunjaya Lakkireddy   +13 more
doaj   +1 more source

Systematic review of the use of intravenous amiodarone and nifekalant for cardiopulmonary resuscitation in Japan

Journal of Arrhythmia, 2014
Background: Intravenous amiodarone is considered to be the first-line drug for the treatment of ventricular tachycardia or fibrillation. However, in Japan, nifekalant had been used before the introduction of amiodarone; therefore, most clinical studies ...
Mari Amino, MD, PhD, Koichiro Yoshioka, MD, PhD, Shigetaka Kanda, MD, Yoshiaki Deguchi, MD, PhD, Mari Nakamura, MD, Yoshinori Kobayashi, MD, PhD, Sadaki Inokuchi, MD, PhD, Teruhisa Tanabe, MD, PhD, Yuji Ikari, MD, PhD   +8 more
doaj   +1 more source

Contemporary characteristics and outcomes in chagasic heart failure compared with other nonischemic and ischemic cardiomyopathy [PDF]

, 2017
Background: Chagas’ disease is an important cause of cardiomyopathy in Latin America. We aimed to compare clinical characteristics and outcomes in patients with heart failure (HF) with reduced ejection fraction caused by Chagas’ disease, with other ...
Claudio R. Gimpelewicz, Efraín A. Gómez, Felipe Martinez, Felix Ramires, Jean L. Rouleau, John J.V. McMurray, Karl Swedberg, Kenneth Dickstein, Lars Køber, Li Shen, Luis Eduardo Echeverría, Luiz Carlos Bodanese, Michael R. Zile, Milton Packer, null null, Pardeep S. Jhund, Scott D. Solomon, William T. Abraham   +17 more
core   +3 more sources

Cardiomyocyte-Targeting Peptide to Deliver Amiodarone

Pharmaceutics, 2023
Background: Amiodarone is underutilized due to significant off-target toxicities. We hypothesized that targeted delivery to the heart would lead to the lowering of the dose by utilizing a cardiomyocyte-targeting peptide (CTP), a cell-penetrating peptide ...
Maliha Zahid, Beth Weber, Ray Yurko, Kazi Islam, Vaishavi Agrawal, Jack Lopuszynski, Hisato Yagi, Guy Salama   +7 more
doaj   +1 more source

Management of amiodarone-related thyroid problems

Therapeutic Advances in Endocrinology and Metabolism, 2011
Amiodarone is a highly effective and well-established antiarrrhythmic drug. It can be used to treat supraventricular and ventricular tachyarrhythmias and has the added advantage of being well tolerated in patients with impaired left ventricular systolic ...
Shashithej K. Narayana, David R. Woods, Christopher J. Boos   +2 more
doaj   +1 more source

Local Use of Hydrogel with Amiodarone in Cardiac Surgery: Experiment and Translation to the Clinic

Gels, 2021
The objective of this study was to study the use of the hydrogel biopolymer based on sodium alginate (“Colegel”) with a drug substance—amiodarone—for the prevention of postoperative atrial fibrillation (POAF) in cardiac surgery.
Vladimir Shvartz, Teymuraz Kanametov, Maria Sokolskaya, Andrey Petrosyan, Tatyana Le, Olga Bockeria, Leo Bockeria   +6 more
doaj   +1 more source

Longitudinal study of patients with chronic Chagas cardiomyopathy in Brazil (SaMi-Trop project): a cohort profile. [PDF]

, 2016
PurposeWe have established a prospective cohort of 1959 patients with chronic Chagas cardiomyopathy to evaluate if a clinical prediction rule based on ECG, brain natriuretic peptide (BNP) levels, and other biomarkers can be useful in clinical practice ...
Bierrenbach, Ana Luiza, Cardoso, Clareci Silva, Cunha-Neto, Edécio, de Oliveira, Lea Campos, Ferreira, Ariela Mota, Ferreira, João Eduardo, Haikal, Desirée Sant'Ana, Oliveira, Claudia Di Lorenzo, Reingold, Arthur L, Ribeiro, Antonio Luiz P, Sabino, Ester Cerdeira   +10 more
core   +3 more sources

Intravenous Amiodarone

Journal of the American College of Cardiology, 1997
Intravenous amiodarone was approved in 1995 for the treatment of malignant and resistant ventricular arrhythmia. Although it is an "old drug," much has been learned recently about this complex drug and its application in a variety of cardiac arrhythmias.
Kowey, Peter R, Marinchak, Roger A, Rials, Seth J, Filart, Roland A   +3 more
openaire   +2 more sources